tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2022 Oct 27;9(11)
fac565.
doi: 10.1093/ofid/ofac565. eCollection 2022 Nov.
Bebtelovimab for High-Risk Outpatients With Early COVID-19 in a Large US Health System
Scott Dryden-Peterson[SUP] 1 2 3 4 5 [/SUP], Andy Kim[SUP] 1 6 5 [/SUP], Mary-Ruth Joyce[SUP] 1 [/SUP], Jennifer A Johnson[SUP] 1 5 [/SUP], Arthur Y Kim[SUP] 6 5 [/SUP], Lindsey R Baden[SUP] 1 5 [/SUP], Ann E Woolley[SUP] 1 5 [/SUP]
Affiliations
Abstract
There are limited data for the clinical efficacy of bebtelovimab in preventing severe coronavirus disease 2019. Among outpatients unable to take nirmatrelvir-ritonavir at a large health system, 10 of 377 (2.7%) patients who received bebtelovimab and 17 of 377 (4.5%) matched untreated patients were hospitalized or died. The 43% observed risk reduction with bebtelovimab was not statistically significant (P = 0.14).
Keywords: SARS-CoV-2; bebtelovimab; COVID-19; monoclonal antibody; pandemic.
. 2022 Oct 27;9(11)
fac565.doi: 10.1093/ofid/ofac565. eCollection 2022 Nov.
Bebtelovimab for High-Risk Outpatients With Early COVID-19 in a Large US Health System
Scott Dryden-Peterson[SUP] 1 2 3 4 5 [/SUP], Andy Kim[SUP] 1 6 5 [/SUP], Mary-Ruth Joyce[SUP] 1 [/SUP], Jennifer A Johnson[SUP] 1 5 [/SUP], Arthur Y Kim[SUP] 6 5 [/SUP], Lindsey R Baden[SUP] 1 5 [/SUP], Ann E Woolley[SUP] 1 5 [/SUP]
Affiliations
- PMID: 36438619
- PMCID: PMC9620388
- DOI: 10.1093/ofid/ofac565
Abstract
There are limited data for the clinical efficacy of bebtelovimab in preventing severe coronavirus disease 2019. Among outpatients unable to take nirmatrelvir-ritonavir at a large health system, 10 of 377 (2.7%) patients who received bebtelovimab and 17 of 377 (4.5%) matched untreated patients were hospitalized or died. The 43% observed risk reduction with bebtelovimab was not statistically significant (P = 0.14).
Keywords: SARS-CoV-2; bebtelovimab; COVID-19; monoclonal antibody; pandemic.